Where are the deals in biopharma? A new analysis of 714 licensing deals and joint ventures from Deloitte shows that cancer was the most active therapeutic area last year, with 161 deals. Infectious disease and neurology has the second and third highest number of deals. Although there were fewer deals in autoimmune & inflammatory diseases and endocrine & metabolic conditions, these areas had high median deal sizes.
Most CEOs of publicly traded health plans saw their salaries go up last year along with company income. The top execs of the seven largest publicly traded health plans made $87 million last year, with Cigna CEO David Cordani making the most ($19.1 million) and Humana’s Mike McCallister making the least ($7.3 million), according to an American Medical News analysis of SEC filings.
Merck won’t be following in the footsteps of Abbott and Pfizer in splitting up the business. ’My philosophy is fix what is broke, don’t do the fad of the day,’ CEO Ken Frazier said at the Sanford C. Bernstein conference yesterday in New York.
Stanford’s StartX accelerator is expanding this summer by creating a program to work specifically with biotech and medical startups. Eleven companies led by Stanford students, faculty will participate in the six-month program.
Even the most aggressive states that have pushed to get their health insurance exchanges up and running fear they won’t be ready for enrollment by the 2014 deadline. The problem? Information technology.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.